Weighing the Evidence: Immunomodulatory Combinations (IO/IO and IO/TKI) for the Treatment of Clear Cell Renal Cell Cancer

Matthew Campbell, MD, MS, and Rana McKay, MD, offer a concise review of existing treatment approaches for clear cell renal cell carcinoma across risk categories, along with considerations for sequencing therapies.

The key opinion leaders explore extended follow-up results from the CheckMate-214 clinical trial.

Rana McKay, MD, examines the pivotal efficacy and safety outcomes from the 8-year follow-up of the CheckMate-214 trial in treatment-naïve patients, presented at ASCO GU 2024, and discusses how these findings impact clinical practice.

Matthew Campbell, MD, MS, analyzes the crucial efficacy and safety results from the CLEAR trial's 4-year final analysis, incorporating insights on how these findings influence clinical decision-making for treatment-naïve patients with advanced renal cell carcinoma.

The key opinion leaders examine the data from the KEYNOTE-426 trial, focusing on safety and efficacy outcomes along with other pertinent updates.

Dr. Campbell evaluates the efficacy and safety results from the 55-month analysis of the CheckMate-9ER trial, and explores the considerations for discontinuing or continuing immunotherapy (IO) in IO/IO versus IO/TKI combination regimens.

Medical experts specializing in clear cell renal cell carcinoma examine the concept of treatment-free survival in immunotherapy/tyrosine kinase inhibitor (IO/TKI) regimens, addressing both the advantages and potential drawbacks.

The key opinion leaders share their strategies for selecting systemic therapy, comparing immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) approaches, for previously untreated patients with advanced renal cell carcinoma.

The panelists compare the adverse event profiles of immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens, and address the economic implications of managing long-term side effects.

The panelists examine the CheckMate-67T study, which evaluated the efficacy and safety of subcutaneous versus intravenous administration of nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma.

Matthew Campbell, MD, MS, and Rana McKay, MD, conclude by addressing the remaining unmet needs and persistent treatment challenges faced in managing patients with advanced renal cell carcinoma.